Polygenic risk for schizophrenia and bipolar disorder in relation to cardiovascular biomarkers

• Published in: European archives of psychiatry and clinical neuroscience 2024-08, Vol.274 (5), p.1223-1230
• Main Authors: Reponen, Elina J., Ueland, Thor, Rokicki, Jaroslav, Bettella, Francesco, Aas, Monica, Werner, Maren C. F., Dieset, Ingrid, Steen, Nils E., Andreassen, Ole A., Tesli, Martin
• Format: Article
• Language: English
• Subjects: Adult; Antipsychotics; Biomarkers; Biomarkers - blood; Bipolar disorder; Bipolar Disorder - blood; Bipolar Disorder - genetics; Body Mass Index; Cardiovascular diseases; Cardiovascular Diseases - blood; Cardiovascular Diseases - genetics; Female; Genetic factors; Genome-Wide Association Study; Humans; Male; Medicine; Medicine & Public Health; Mental disorders; Middle Aged; Multifactorial Inheritance; Neurosciences; Original Paper; Plasma levels; Psychiatry; Psychosis; Regression analysis; Schizophrenia; Schizophrenia - blood; Schizophrenia - genetics
• ISSN: 0940-1334; 1433-8491; 1433-8491
• DOI: 10.1007/s00406-023-01591-0

Individuals with schizophrenia and bipolar disorder are at an increased risk of cardiovascular disease (CVD), and a range of biomarkers related to CVD risk have been found to be abnormal in these patients. Common genetic factors are a putative underlying mechanism, alongside lifestyle factors and antipsychotic medication. However, the extent to which the altered CVD biomarkers are related to genetic factors involved in schizophrenia and bipolar disorder is unknown. In a sample including 699 patients with schizophrenia, 391 with bipolar disorder, and 822 healthy controls, we evaluated 8 CVD risk biomarkers, including BMI, and fasting plasma levels of CVD biomarkers from a subsample. Polygenic risk scores (PGRS) were obtained from genome-wide associations studies (GWAS) of schizophrenia and bipolar disorder from the Psychiatric Genomics Consortium. The CVD biomarkers were used as outcome variables in linear regression models including schizophrenia and bipolar disorder PGRS as predictors, age, sex, diagnostic category, batch and 10 principal components as covariates, controlling for multiple testing by Bonferroni correction for the number of independent tests. Bipolar disorder PGRS was significantly ( p  = 0.03) negatively associated with BMI after multiple testing correction, and schizophrenia PGRS was nominally negatively associated with BMI. There were no other significant associations between bipolar or schizophrenia PGRS, and other investigated CVD biomarkers. Despite a range of abnormal CVD risk biomarkers in psychotic disorders, we only found a significant negative association between bipolar disorder PGRS and BMI. This has previously been shown for schizophrenia PGRS and BMI, and warrants further exploration.